Last reviewed · How we verify
Oral disulfiram
At a glance
| Generic name | Oral disulfiram |
|---|---|
| Also known as | Antabuse |
| Sponsor | University of Rochester |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Fatigue
- Dizziness
- Lymphocyte count decreased
- Headache
- Memory impairment
- Alopecia
- Constipation
- Platelet count decreased
- Tremor
- Depression
- Diarrhea
Key clinical trials
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (PHASE1)
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma (PHASE2)
- The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration (PHASE1)
- Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma (PHASE1, PHASE2)
- The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes (PHASE4)
- Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme (PHASE2)
- Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART (PHASE1, PHASE2)
- Canagliflozin With Gemcitabine in Pancreatic Carcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral disulfiram CI brief — competitive landscape report
- Oral disulfiram updates RSS · CI watch RSS
- University of Rochester portfolio CI